Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of ...

The "Sorafenib Market Report 2025" has been added to ResearchAndMarkets.com's offering.This Sorafenib market report provides a comprehensive analysis of the market's characteristics, size, and growth, ...

With his research group "Chromatin and SUMO Physiology," the molecular biologist has shown that the chemotherapeutic agent sorafenib actively remodels skeletal muscle cells and thus triggers cachexia.

Purpose: The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed. Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer ...

Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib significantly improved ...

HealthDay News — The US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or metastatic hepatocellular ...